EUVIMEDEUVIMED entdecken
Crossref

Levosalbutamol Efficacy and Safety in Children with Mild Exacerbation of Bronchial Asthma: Real Clinical Practice Data

Andrey V. Kamaev, Yuliya B. Klukhina, Olga V. Trusova, Dmitriy S. Korostovtsev

Pediatric pharmacology · 26.07.2026 · 23 (3) · 185-193

DOI: 10.15690/pf.v23i3.3063 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric pharmacology, online erschienen am 26.07.2026. Verfasst von Andrey V. Kamaev und 3 weiteren Autor:innen. Die Arbeit nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Reliever medication is necessary for every patient with bronchial asthma (BA) during exacerbation. Active stereoisomeric preparations are safer than racemic mixtures, conserving comparable efficacy. Pressurized metered dose inhaler (pMDI) levosalbutamol is registered for usage in Russia from age 4 years old, but pediatric population studies are insufficient. The aim of the study is to evaluate levosalbutamol pMDI 45 mcg/dose efficacy and safety in treating BA exacerbations in pediatric patients in real clinical practice. Materials and methods . 62 patients from 6 to 17 years old (mean age 9.8 ± 1.3 years) on maintenance treatment of low and medium dose inhalation glucocorticosteroids monotherapy were included during BA exacerbation. The study observation period lasted 7 ± 2 days. Levosalbutamol pMDI 45 mcg/dose was prescribed daily before maintenance inhalations and as needed, but no more than 8 doses per day. Asthma symptoms were evaluated by point-scale, spirometry with bronchodilator test was performed on inclusion visit and week after. Patients daily recorded complaitns and adverse events.

Results

All included patients had finished the study as per protocol. When conducting a bronchodilator test with levosalbutamol MDI at a dose of 90–180 mcg 15 minutes after inhalation in children under 12 years of age, the average score for the severity of asthma exacerbation symptoms decreased from 4.6 ± 1.3 to 1.5 ± 0.9 points (p = 0.0032), and the forced expiratory volume in the first second increased by 15.7 ± 2.8%. Any adverse events (AE) during 7 days were registered in 5 (8.1%) patients; cough was most prevalent (6.5%). There were no cases of preterm discontinuation due to AE or serious AE. At visit 2 no patient was registered with asthma exacerbation. There were no cases of tachyphylaxis in terms of bronchodilation due to levosalbutamol.

Conclusion

According to our data, levosalbutamol pMDI 45 mcg/dose administration has clinically significant bronchodilation effect and favorable safety profile in 6–17 years old children.

Zitieren

APA

Kamaev, A. V., Klukhina, Y. B., Trusova, O. V., & Korostovtsev, D. S. (2026). Levosalbutamol Efficacy and Safety in Children with Mild Exacerbation of Bronchial Asthma: Real Clinical Practice Data. Pediatric pharmacology, 23(3), 185-193. https://doi.org/10.15690/pf.v23i3.3063

Vancouver

Kamaev AV, Klukhina YB, Trusova OV, Korostovtsev DS. Levosalbutamol Efficacy and Safety in Children with Mild Exacerbation of Bronchial Asthma: Real Clinical Practice Data. Pediatric pharmacology. 2026;23(3):185-193. doi:10.15690/pf.v23i3.3063

BibTeX
@article{Kamaev2026,
  author = {Kamaev, Andrey V. and Klukhina, Yuliya B. and Trusova, Olga V. and Korostovtsev, Dmitriy S.},
  title = {Levosalbutamol Efficacy and Safety in Children with Mild Exacerbation of Bronchial Asthma: Real Clinical Practice Data},
  journal = {Pediatric pharmacology},
  year = {2026},
  volume = {23},
  number = {3},
  pages = {185--193},
  doi = {10.15690/pf.v23i3.3063}
}
Kostenlos starten →